prednisone has been researched along with orteronel in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agus, DB; Bargfrede, M; Carthon, B; Clark, WR; Gandhi, JG; Heath, E; Kong, N; Lin, J; Liu, G; Moran, S; Oh, WK; Petrylak, DP; Suri, A | 1 |
| Agarwal, N; Agus, D; Bellmunt, J; Borgstein, N; Carcano, F; Cruz, FM; De Bono, J; de Wit, R; Dreicer, R; Efstathiou, E; Fizazi, K; Fountzilas, G; Jones, R; Lee, SY; Oudard, S; Petrylak, DP; Saad, F; Tejura, B; Ulys, A; Webb, IJ | 1 |
| Akaza, H; de Wit, R; Dreicer, R; Efstathiou, E; Fizazi, K; Fong, PC; Hart, LL; Jinga, V; Jones, R; MacLean, DB; McDermott, R; Nelson, J; Saad, F; Scher, HI; Suzuki, K; Wang, L; Webb, IJ; Wirth, M | 1 |
| Abbott, DH; Bird, IM | 1 |
1 review(s) available for prednisone and orteronel
| Article | Year |
|---|---|
The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Topics: Adrenal Hyperplasia, Congenital; Androstadienes; Androstenes; Antineoplastic Agents; Benzimidazoles; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Male; Naphthalenes; Prednisone; Prostate; Prostatic Neoplasms; Protective Factors; Steroid 17-alpha-Hydroxylase; Triazoles | 2016 |
3 trial(s) available for prednisone and orteronel
| Article | Year |
|---|---|
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dehydroepiandrosterone Sulfate; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Male; Middle Aged; Naphthalenes; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone | 2015 |
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy:
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Europe; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Naphthalenes; Neoplasm Grading; North America; Odds Ratio; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2015 |
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Cytochrome P-450 Enzyme Inhibitors; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Humans; Imidazoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Naphthalenes; New Zealand; North America; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Risk Factors; Steroid 17-alpha-Hydroxylase; Time Factors; Treatment Outcome | 2015 |